New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 4, 2025 - Supernus Pharmaceuticals announced the FDA approval of Onapgo (apomorphine), for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.
Download PDF
Return to publications
